Find trials
Search tips

Left Ventricular Assist Device Glycemic Control Evaluation by Continuous Glucose Monitor Compared With a1c

Overview

About this study

The purpose of this study is to determine if HgbA1c will underestimate average glucose obtained over a 3-month period in a cohort of diabetic LVAD-supported patients. Also, to see if continous glucose monitor: (CGM) data will facilitate improved antihyperglycemic decision making in diabetic patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • At least 18 years of age.
  • Previous diagnosis of type II diabetes mellitus on antihyperglycemics.
  • Cell phone capable of uploading glycemic data through the Libre 3 app.
  • Willing to give informed consent.

Exclusion Criteria:

  • Type I diabetes mellitus.
  • Unable to return at 3 month evaluation.
  • Unwillingness to provide informed consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/14/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrew Rosenbaum, M.D.

Open for enrollment

Contact information:

Andrew Rosenbaum M.D.

(507) 422-5118

Rosenbaum.Andrew@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20545056

Mayo Clinic Footer